The influence of local instillation of fusidic acid on the development of microbial complications after lung resection.
The efficacy of local instillation of fusidic acid in the prevention of post-surgical microbial complications during various types of lung resection was studied. Four hundred ninety two consecutive patients who underwent 504 thoracotomies for non-small cell lung carcinoma during April 1998-May 2004 were reviewed. The 290 patients of the first period who underwent 298 thoracotomies received a chemoprophylactic regimen of intravenous cefuroxime while the 202 patients of the second period who underwent 206 thoracotomies were additionally treated with fusidic acid, irrigated with local instillation into the pleural space, for the prevention of postoperative septic complications. Patients were followed postoperatively for development of septic complications (empyema and bronchopleural fistula) as well as of pneumonia and wound infection. Seventeen patients (5.7%) of the first period developed empyema and 13 fistula (4.4%), whereas only 2 patients (1.0%) of the second period developed empyema and fistula (OR = 5.876; 95% CI, 1.343- 25.716; P = 0.008 and OR = 4.193; 95% CI, 1.003-20.130; P = 0.034, respectively). Cases of pneumonia decreased, but not significantly, from 21 (7.0%) during the first period to 9 (4.4%) during the second period (OR = 1.613; 95% CI, 0.724-3.593; P = 0.257) while cases of wound infection decreased significantly from 19 (6.4%) to 2 (1.0%) (OR = 6.567; 95% CI, 1.513-28.510; P = 0.003). During the first period 23 pathogens were found from cases of empyema and 73 pathogens from cases of pneumonia and wound infection, whereas during the second period 3 and 18 pathogens were respectively found (OR = 5.3; 95% CI, 1.570-17.888; P = 0.003, and OR = 2.804; 95% CI, 1.628-4.838; P <0.001, respectively). These results indicate that local instillation of fusidic acid in the pleural space prior to lung resection seems effective in reducing the rate of septic complications as well as of wound infections.
Baltayiannis
N
N
Department of Thoracic Surgery, Metaxa Cancer Hospital, Piraeus, Greece.
Markogiannakis
A
A
Sfyridis
P
P
Manolis
E N
EN
Anagnostopoulos
D
D
Bolanos
N
N
Hatzimichalis
A
A
Tsakris
A
A
D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D019072:Antibiotic Prophylaxis; D001424:Bacterial Infections / Q000382:microbiology / Q000517:prevention & control*; D001983:Bronchial Fistula / Q000382:microbiology / Q000517:prevention & control; D002289:Carcinoma, Non-Small-Cell Lung / Q000601:surgery*; D002444:Cefuroxime / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D016724:Empyema, Pleural / Q000382:microbiology / Q000517:prevention & control; D005260:Female; D005672:Fusidic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007322:Instillation, Drug; D008175:Lung Neoplasms / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D018410:Pneumonia, Bacterial / Q000382:microbiology / Q000517:prevention & control; D011183:Postoperative Complications / Q000382:microbiology / Q000517:prevention & control*; D012189:Retrospective Studies; D013530:Surgical Wound Infection / Q000382:microbiology / Q000517:prevention & control; D013908:Thoracotomy
D000900:Anti-Bacterial Agents; D005672:Fusidic Acid; D002444:Cefuroxime